In this article, we discuss the 8 stocks to buy according to Devesh Gandhi’s SilverArc Capital based on Q1 holdings of the fund.
Devesh Gandhi is President at SilverArc Capital. His rich experience spans renowned financial firms, starting from McKinsey & Company. His last job was as Senior Analyst at Sonar Capital, where he served for 6 years. In 2012, he started SilverArc Capital, a firm based out of Boston. This is an investment management firm and has a focus on the healthcare sector.
Photo by Nick Chong on Unsplash
Some notable stock picks of Devesh Gandhi’s SilverArc Capital include Apellis Pharmaceuticals Inc. (NASDAQ:APLS), Adamas Pharmaceuticals Inc (NASDAQ:ADMS), and Verastem Inc. (NASDAQ:VSTM).
8. Insmed Incorporated (NASDAQ:INSM)
SilverArc Capital’s Stake Value: $2.4 million
Insmed Inc (NASDAQ:INSM) is a global biopharmaceutical company and works for a mission to transform the lives of patients suffering from serious and rare diseases. The company intends to initiate a Phase 2 study of TPIP in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) in early 2022.
7. ImmunoGen, Inc. (NASDAQ:IMGN)
SilverArc Capital’s Stake Value: $3.0 million
Immunogen Inc. (NASDAQ:IMGN) is a clinical-stage biotechnology company based out of the United States. Its focus is an antibody-drug conjugate, or ADC, technology, that uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-destroying agent.
6. Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) hv
SilverArc Capital’s Stake Value: $4.4 million
Biohaven Pharmaceutical Holding Co Ltd. (NYSE:BHVN) is a clinical-stage biopharmaceutical company that has proven leadership in industry and academic settings.
Insider Monkey’s data shows that 31 hedge funds held stakes in the company at the end of the fourth quarter of 2021.
In its first-quarter 2021 investor letter, Baron Health Care Fund mentioned Biohaven Pharmaceutical Holding Co Ltd. (NYSE:BHVN). Here is what the fund said:
“Biohaven Pharmaceutical Holding Company Ltd. is a biotechnology company dedicated to neurologic drug discovery. It launched its lead asset, migraine medication Nurtec, last year, and the company is transitioning towards profitability. Shares declined when Biohaven issued a secondary offering in March that took investors by surprise and seemed early in relation to an expected second indication for Nurtec in the prophylactic prevention of migraine, which expands its market. We exited our position.”
5. Amryt Pharma plc (NASDAQ:AMYT)
SilverArc Capital’s Stake Value: $1.2 million
Amryt Pharma Plc (NASDAQ:AMYT) is a specialty pharmaceutical company that focuses on developing and delivering new treatments to improve the lives of patients with rare or orphan diseases.
At the end of the fourth quarter of 2021, 17 hedge funds in the database of Insider Monkey held stakes in the company.
4. Morphic Holding, Inc. (NASDAQ:MORF)
SilverArc Capital’s Stake Value: $2.8 million
Morphic Holding Inc. (NASDAQ:MORF) is a biopharmaceutical company and is leading the development of a new generation of oral integrin drugs. It stands fourth on our list of 8 stocks to buy according to Devesh Gandhi’s SilverArc Capital.
At the end of the second quarter of 2021, 16 hedge funds in the database of Insider Monkey held stakes in the company.
3. Veracyte, Inc. (NASDAQ:VCYT)
SilverArc Capital’s Stake Value: $11.7 million
Veracyte Inc. (NASDAQ:VCYT) is a genomic diagnostics company and has a product portfolio with products such as Afirma analysis, Percepta, Envisia, and others.
In the Q2 2021 investor letter, Artisan Partners mentioned Veracyte, Inc. (NASDAQ: VCYT). Here is what the fund said:
“Among our bottom contributors (includes) Veracyte. Veracyte develops and markets molecular tests designed to minimize ambiguity in the treatment of patients with cancer. These tests can reduce unnecessary surgeries and help put cancer patients at ease when the decision is to “watch and wait.” Shares have been pressured amid a recent investment cycle (acquired Decipher and HalioDX) and a resurgence of the pandemic earlier this year weighing on testing volumes. In addition, the company’s founder and CEO recently announced she was moving to Executive Chair. Her replacement is the former CFO of Illumina, who is very knowledgeable in invitro diagnostics and played a critical role in Illumina’s international expansion efforts (which we expect him to pursue at Veracyte). We are maintaining our position as patients return to the clinic for testing and as management executes on its strong R&D pipeline, including the upcoming launch of a nasal swab lung cancer test. Longer-term, the company is well-positioned to expand internationally as it ports its growing menu of tests onto the recently acquired nCounter instrument.”
2. Mirati Therapeutics, Inc. (NASDAQ:MRTX)
SilverArc Capital’s Stake Value: $3.8 million
Mirati Therapeutics Inc. (NASDAQ:MRTX) is a clinical-stage targeted oncology company with a mission to discover, design and deliver breakthrough therapies.
At the end of the fourth quarter of 2021, 46 hedge funds in the database of Insider Monkey held stakes worth in the company.
1. Merus N.V. (NASDAQ:MRUS)
SilverArc Capital’s Stake Value: $8.6 million
Merus N.v. (NASDAQ:MRUS) works on clinically advancing leading-edge, targeted treatments to address the unmet needs of patients having various types of cancer.
At the end of the fourth quarter of 2021, 37 hedge funds in the database of Insider Monkey held stakes in the company.
Citigroup analyst Yigal Nochomovitz raised his price target on Merus N.v. (NASDAQ:MRUS) to $38.0 from $31.0 and re-affirmed his “Buy” rating on the stock.
You can also take a peek at 10 Best Stocks Under $10 to Buy Right Now and 10 Best Oil Stocks to Buy Amid Post-COVID Demand Boom and Price Volatility.
Follow Insider Monkey on Twitter
Suggested articles:
- 15 Best Semiconductor Stocks to Buy Now
- 15 Best Energy Stocks to Buy Now
- 10 Best Dividend Stocks to Buy According to Billionaire Howard Marks
Disclosure: None. 8 Stocks to Buy According to Devesh Gandhi’s SilverArc Capital is originally published on Insider Monkey.
